SWOG clinical trial number
CTSU/E1505

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

Closed
Phase
Published
Abbreviated Title
Phase III Adjuvant Chemo and/or Bevacizumab in NSCLC
Activated
07/01/2007
Closed
09/20/2013
Participants
CTSU

Research committees

Lung Cancer

Treatment

Cisplatin Docetaxel Gemcitabine hydrochloride Vinorelbine tartrate Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

C Steuer;O Jegede;S Dahlberg;H Wakelee;S Keller;W Tester;D Gandara;S Graziano;A Adjei;C Butts;S Ramalingam;J Schiller Journal of Thoracic Oncology Jun;16(6):960-967. doi: 10.1016/j.jtho.2020.12.017. Epub 2021 Feb 1.

PMid: PMID33539971 | PMC number: PMC8383783

2019

E1505: Adjuvant Chemotherapy +/- Bevacizumab for early stage NSCLC: Updated chemotherapy subset analysis

H Wakelee;SE Dahlberg;S Keller;WJ Tester;DR Gandara;S Graziano;A Adjei;N Leighl;CA Butts;S Aisner;J Rothman;J Patel;MD Sborov;S McDermott;R Perez-Soler;A Traynor;TL Evans;S Ramalingam;JH Schiller WCLC IASCLC Annual Meeting (September 7-10, 2019, Barcelona, Spain), accepted, mini-oral presentation

2017

Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505

H Wakelee;S Dahlberg;S Keller;WJ Tester;D Gandara;S Graziano;A Adjei;N Leighl;S Aisner;J Rothman;J Patel;MD Sborov;S McDermott;R Perez-Soler;A Traynor;C Butts;T Evans;L Horn;S Ramalingam;JH Schiller Lancet Oncology Dec;18(12):1610-1623, 2017; Nov 9 [Epub ahead of print]

PMid: PMID29129443 | PMC number: PMC5789803

2016

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets

H Wakelee;S Dahlberg;S Keller;W Tester;D Gandara;S Graziano;A Adjei;N Leighl;C Butts;S Aisner;J Rothman;J Patel;M Sborov;R McDermott;R Perez-Soler;A Traynor;T Evans;L Horn;S Ramalingam;J Schiller Journal of Clinical Oncology 34, 2016 (suppl; abstr 8507); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral session

2011

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early stage non-small cell lung cancer (NSCLC)

H Wakelee;S Dahlberg;S Keller;DR Gandara;SL Graziano;AA Adjei;JH Schiller Journal of Clinical Oncology 29:(suppl; abstr 7013)ASCO 2011 Annual Meeting, poster discussion presentation

Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer (NSCLC)

H Wakelee;S Dahlberg;S Keller;DR Gandara;S Graziano;N Leigh;A Adjei;J Schiller J Thorac Oncol. 2011; 6(6)(suppl 2): S464. abstract 042.03; IASLC, 14th World Conference on Lung Cancer, oral presentation;

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A082304/S2402

Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317
Research Committee(s)
Lung Cancer
Activated
12/11/2024
Open